Skip to main content
Research

Current Research

ALZHEIMER’S DISEASE RESEARCH

BAN: A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease

If you’re between 50 and 90 years of age and have noticeable changes in your memory, judgment or ability to perform your daily activities, you may qualify for the BAN study. People with Alzheimer’s disease have a build-up of abnormal protein known as amyloid in their brains. BAN2401 is thought to reduce the amount of this abnormal protein. 

Interested patients will be consented to begin screening procedures such as memory assessments, physical, labs, MRI and PET scan at no cost. If qualified, participants will visit our site twice per month for an infusion of the study drug. This is a Phase 2 trial.

For more information, please contact Amanda Jamison at 716-819-4117.

 

A4: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

If you are a healthy older adult with normal memory, this could be the right time for you to join the fight to prevent the memory loss of Alzheimer’s disease. This study is for Healthy older individuals, 65 to 85 years of age, who have not shown signs of memory loss and are not taking medications for memory difficulties.

Interested patients will be consented to begin screening procedures such as memory assessments, physical, labs, MRI and PET scan at no cost. If qualified, participants will visit our site once per month for an infusion of the study drug. Scientists believe that AD-related damage to the brain begins many years before the symptoms of memory loss emerge.  It is hoped that starting treatment very early will help slow the progression of memory loss.
This is a Phase 3 trial.

For more information, please contact Caroline Kumm at 716-558-3492.

 

CREAD: Study of Crenezumab in Patient’s with Prodromal to Mild Alzheimer’s disease

This Phase 3 trial is looking for people ages 50-85 in the early stages of memory issues to take part in a 2 year study of an investigational drug. In this study, participants will get either Crenezumab or placebo in addition to any background therapy you may or
may not be receiving. 

Interested patients will be consented to begin screening procedures such as memory assessments, physical, labs, MRI and PET scan at no cost. If qualified, participants will visit our site once per month for an infusion of the study drug. It is hoped that, if it works, Crenezumab may slow down how fast the disease progresses. 

For more information, please contact Amanda Jamison at 716-819-4117.

 

RECOGNITION:  Study of Piromelatine in Patients with Mild Dementia Due to Alzheimer’s Disease

The purpose of this Phase 2 research study is to determine an effective dose of a once a day tablet, piromelatine, in patients with Mild AD between the ages of 60-85.

The study will take place over 7 months and include visits to our site and weekly telephone calls. The potential sleep enhancing capacities of piromelatine may also be important to the study. Recent clinical and biochemical evidence has identified an interesting link between sleep, cognitive dysfunction and Alzheimer's disease. Patients will be randomly assigned by chance to receive either piromelatine (5mg, 20mg, or 50mg) or placebo.

For more information, please contact Amanda Jamison at 716-819-4117.

 

BRAIN TUMOR/ONCOLOGY RESEARCH

For information regarding brain tumor and oncology research contact Rebecca Hogan, Clinical Research Coordinator, at 716-558-5670

 

EPILEPSY RESEARCH

DZNS-EP-1019: A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Diazepam is well-known and accepted as a drug used to treat seizures and other disorders for over 50 years. This is a research study of an investigational preparation of diazepam given as a nasal spray.     

The study population will comprise two cohorts: Cohort 1 subjects will have refractory epilepsy but are not required to have had recent daily seizures; Cohort 2 subjects will have refractory epilepsy and are required to have multiple daily seizures.

For more information, please contact Amanda Jamison at 716-819-4117.

 

HEADACHE/MIGRAINE RESEARCH

FORWARD Study: Evaluating preventive treatment options for Chronic Migraine

To qualify for this study, you must:

  • Be between 18 to 65 years of age
  • Suffer from migraine
  • Have 15 or more dates with headache each month

 

If you are qualified you will receive at no cost to you study medication, study related care
from a local doctor, compensation for your time for completed visits.

*Health insurance and physician referrals aren’t required to participate*

If you are interested in participating, please call 716-558-5670.

 

Pathway CH-2 Cluster Headache Study

To qualify you must have been diagnosed with chronic cluster headache and have found preventive and/or acute cluster headache treatments to be inadequate for you. 

To participate in this study you must:

  • Have been diagnosed with chronic cluster headache according to the 2013 ICHD criteria
  • Be at least 22 years of age
  • Suffer from at least 4 cluster attacks per week on the side where you typically feel attacks
  • Have judged, with your doctor, that previously or currently used medication treatment for your cluster headache are inadequate for you.
  • Be able to distinguish cluster attacks from other headaches such as migraine or tension-type headaches

If you are interested in participating, please call 716-558-5670.

 

TREXIMET Aura Clinical Trial

Sponsored by Laszlo L. Mechtler, M.D.

A parallel two arm, double blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.

Qualified participants will be:

  • 18 to 50 years of age, inclusive
  • Carry a diagnosis of 1-2 migraine with aura per month for at least three months before study inclusion
  • Have an onset of a visual aura that occurs 15-30 minutes before a migraine headache
  • Able to understand and complete a migraine diary
  • In generally good health as confirmed by medical and medication history
    • a) postmenopausal for one year,
      b) surgically sterile,
      c) on acceptable birth control for at least 1 month prior to screening and throughout the study, or
      d) practicing abstinence and agree to continue same throughout study.

If you are interested in participating, please call 716-558-5670.

 

MAJOR DEPRESSIVE DISORDER RESEARCH

LVM-MD-11: Safety and Efficacy of Levomilnacipran ER (Fetzima) in Adolescent Patients With Major Depressive Disorder

The purpose of this research study is to evaluate the drug levomilnacipran extended-release for how well the drug works, the side effects, and how well tolerated compared to placebo in adolescents (12-17 years of age) with depression. 

Participation will last about 10 weeks and will include 9 visits to the study center. Patient’s will be randomly assigned study drug to compare Levomilnacipran ER 40 mg/day, Levomilnacipran ER 80 mg/day, Fluoxetine (Prozac) 20 mg/day, and placebo. All tablets will look the same.

For more information, please contact Caroline Kumm at 716-558-3492.

 

MÉNIÈRE’S DISEASE RESEARCH STUDY SEEKS VOLUNTEERS

More than 600,000 people in the US suffer from Ménière’s disease, a disorder of the inner ear which can affect balance and hearing. Patients may experience vertigo (a feeling that the patient’s surroundings are moving when they are not), dizziness, nausea, hearing loss, or ringing in the ears.

The Ménière’s disease research study is currently seeking female and male volunteers who are between 18 and 85, have been diagnosed with unilateral (one ear only) Ménière’s disease, and have documented hearing loss. The purpose of this research study is to evaluate the safety and effectiveness of an investigational drug.

Study participants will receive study-related exams, lab tests, and investigational study medication at no charge.

For more information and to see if you may qualify, call 888-205-5801 or visit www.OtonomyResearch.com today!

 

MULTIPLE SCLEROSIS RESEARCH

ASSESS: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod (Gilenya) vs. Copaxone

If you have relapsing-remitting multiple sclerosis (RRMS) and are between the ages of 18-65, you may want to join this study evaluating a new investigational drug that may help you reduce you relapses.

For this one year study, you must have 1 documented relapse in the past year or 2 documented relapses in the last 2 years. Participants must be treatment naïve to Gilenya.

Qualified volunteers will receive study-related medical evaluations, including MRI’s and study drug at no cost. Compensation for time and reasonable reimbursement for travel related expenses are available.

For more information, please contact Amanda Jamison at 716-819-4117.

 

MITIGATE:  Study of Montelukast (Singular) on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera 

If you have relapsing-remitting multiple sclerosis (RRMS) and are over the age of 18, you may want to join this study evaluating a new investigational drug that may help you reduce GI side effects of taking Tecfidera.

For this 12 weeks study, you must have a prescription from your doctor for Tecfidera, and begin taking it at your enrollment for this trial. Singular will be provided to you at no cost. Compensation for time and reasonable reimbursement for travel related expenses are available.

For more information, please contact Amanda Jamison at 716-819-4117.

 

PASSAGE: Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

For this study, relapsing-remitting multiple sclerosis (RRMS) participants must be starting either Gilenya at time of study entry, starting another approved DMT, or have started a DMT within the past 6 months: Betaseron, Extavia, Avonex, Rebif, Copaxone, Aubagio and Tecfidera.

For more information, please contact Caroline Kumm at 716-558-3492.

 

RESTLESS LEG SYNDROME RESEARCH

XP109: Efficacy and Safety Evaluation of HORIZANT in Adolescents Aged 13 to 17 Years Old with Moderate-to-Severe Primary Restless Legs Syndrome

HORIZANT has been studied in adults with restless legs syndrome and is approved by the Food and Drug Administration (FDA) for adults, however it has not been approved by the FDA for teenagers. 

In this study some participants receive HORIZANT and some participants receive a placebo.

For this study you will take 2 tablets of study drug daily for 12 weeks. To find out how well HORIZANT works, 2 different doses of HORIZANT (300 mg or 600 mg) will be compared to placebo, but no one will know until the study is over which study drug a study participant was taking during the study. After completion of this trial, you can continue to the Open Label study, which means all participants receive HORIZANT.

For more information, please contact Caroline Kumm at 716-558-3492.